Health Care [ 9/12 ] | Biotechnology [ 56/73 ]
NASDAQ | Common Stock
ImmunoPrecise Antibodies Ltd. operates as a techbio company.
It leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies; and support the discovery and development of therapeutic antibodies.
The company's contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based on building custom immune libraries from various species; DeepDisplay, a technology utilizing a combination of transgenic animal platforms; bispecific Abthena technology; antibody humanization services; affinity maturation services; antibody development services; protein manufacturing; and cell line development services of target proteins or antibodies.
It is also involved in the development and licensing of antibody discovery platforms and related IP assets.
The company was founded in 1983 and is headquartered in Austin, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 25 | -0.46 Decreased by -319.91% | -0.06 Decreased by -724.82% |
| Dec 12, 24 | -0.06 Increased by +36.30% | -0.07 Increased by +9.00% |
| Sep 16, 24 | -0.11 Increased by +21.43% | -0.08 Decreased by -37.50% |
| Jul 29, 24 | -0.11 Increased by +47.62% | -0.11 |
| Mar 14, 24 | -0.11 Increased by +42.11% | -0.10 Decreased by -10.00% |
| Dec 14, 23 | -0.10 Increased by +66.67% | -0.13 Increased by +23.08% |
| Sep 14, 23 | -0.14 Increased by +63.16% | -0.20 Increased by +30.00% |
| Jul 7, 23 | -0.21 Increased by +4.55% | -0.17 Decreased by -23.53% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jan 31, 25 | 6.15 M Decreased by -1.13% | -21.52 M Decreased by -703.32% | Decreased by -349.88% Decreased by -712.46% |
| Oct 31, 24 | 6.13 M Decreased by -0.41% | -2.55 M Increased by +2.63% | Decreased by -41.68% Increased by +2.23% |
| Jul 31, 24 | 5.26 M Decreased by -7.47% | -4.00 M Decreased by -17.07% | Decreased by -75.98% Decreased by -26.52% |
| Apr 30, 24 | 6.46 M Increased by +14.91% | -18.05 M Decreased by -251.82% | Decreased by -279.38% Decreased by -206.18% |
| Jan 31, 24 | 6.22 M Increased by +20.31% | -2.68 M Increased by +42.99% | Decreased by -43.06% Increased by +52.61% |
| Oct 31, 23 | 6.15 M Increased by +18.63% | -2.62 M Increased by +64.33% | Decreased by -42.63% Increased by +69.93% |
| Jul 31, 23 | 5.69 M Increased by +21.31% | -3.42 M Increased by +63.59% | Decreased by -60.06% Increased by +69.98% |
| Apr 30, 23 | 5.62 M Increased by +7.29% | -5.13 M Decreased by -10.44% | Decreased by -91.25% Decreased by -2.94% |